TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26684872

Group type: EXPERIMENTAL
Intervention: Medical and Mental Health Unit (MMHU)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MMHU
Number of subjects: 600
Study: 23194084

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 1 mg/day
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (1, 2.5, 5, or 10 mg/day)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 21252308

Group type: EXPERIMENTAL
Intervention: Treadmill walking at systematically increased speeds
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treadmill walking at self-selected speed
Number of subjects: 20
Study: 18471631

Group type: EXPERIMENTAL
Intervention: AF‐1 (UY) IOL (blue-light-filtering)
Number of subjects: 2

Group type: COMPARATOR
Intervention: AF‐1 (UV) IOL (clear)
Number of subjects: 2
Study: 16542747

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² on day 1 and gemcitabine 1,200 mg/m² on days 1 and 8, every 3 weeks for four courses (CG regimen)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 10 mg/m² on day 1, methotrexate 35 mg/m² on day 1, and mitomycin 7 mg/m² on day 1, every 3 weeks with mitomycin in alternate cycles for four courses (MMM regimen)
Number of subjects: 54
Study: 14515196

Group type: EXPERIMENTAL
Intervention: 15 mg prinomastat plus gemcitabine/cisplatin (GC)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: 15 mg prinomastat plus paclitaxel/carboplatin (PC)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: 15 mg prinomastat alone (post‐discontinuation of chemotherapy)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 1023

Group type: COMPARATOR
Intervention: 5 or 10 mg prinomastat plus chemotherapy
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Central venous catheter placed within 3 months
Number of subjects: 1023
Study: 11198727

Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethyl succinate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 9254871

Group type: EXPERIMENTAL
Intervention: Personal invitation letter for a routine mammogram at a specific time
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard invitation letters (4 different styles)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Clinical breast examination within the previous year
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Recommendation from a health professional for routine mammography
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Perception of mammography as efficient in early detection of breast cancer
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Aggressiveness of message details or signature from a family physician or higher authority
Number of subjects: 1500
Study: 8483865

Group type: EXPERIMENTAL
Intervention: Interest in genetic testing for colon cancer susceptibility
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Perceived risk for colon cancer
Number of subjects: 401

Group type: COMPARATOR
Intervention: Different question frames
Number of subjects: 401
Study: 2935242

Group type: EXPERIMENTAL
Intervention: IA FUDR (0.3‐0.1 mg/kg/day X 14, every 28 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: IV FUDR (0.05‐0.15 mg/kg/day X 14, every 28 days)
Number of subjects: 86
Study: 30203481

Group type: EXPERIMENTAL
Intervention: Galaxy Rescuers game (game-only group)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Galaxy Rescuers game (game-with-debriefing group)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Game satisfaction survey
Number of subjects: 328
Study: 27733522

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (7 mg/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Potassium chloride (placebo)
Number of subjects: 20
Study: 1578948

Group type: EXPERIMENTAL
Intervention: 5‐day courses of ARA‐C plus thioguanine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose ARA‐C (HDARAC) plus Asparaginase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idarubicin or Daunorubicin in combination with Cytarabine in a standard 3+7 protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate dose ARA‐A (IDARAC) plus Mitoxantrone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative treatment with Thioguanine and ARA‐C
Number of subjects: 0
Study: 22782949

Group type: EXPERIMENTAL
Intervention: 15 µg adjuvanted vaccine
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: 7.5 µg adjuvanted vaccine
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: 3.75 µg adjuvanted vaccine
Number of subjects: 789

Group type: COMPARATOR
Intervention: 15 µg unadjuvanted vaccine
Number of subjects: 789
Study: 20075020

Group type: EXPERIMENTAL
Intervention: TETRA base station signal
Number of subjects: 183

Group type: COMPARATOR
Intervention: Sham (no signal)
Number of subjects: 183
Study: 19124357

Group type: EXPERIMENTAL
Intervention: Arformoterol 50 microg QD
Number of subjects: 793

Group type: COMPARATOR
Intervention: Salmeterol 42 microg BID
Number of subjects: 793
Study: 15817866

Group type: EXPERIMENTAL
Intervention: Formula supplemented with DHA (0.36%) and ARA (0.72%)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control formula with no DHA or ARA
Number of subjects: 103
Study: 12502678

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Regular human insulin
Number of subjects: 15

Group type: COMPARATOR
Intervention: No insulin
Number of subjects: 15
Study: 10232178

Group type: EXPERIMENTAL
Intervention: Summer months (May to July)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: School months (August to October)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lack of consistency in summer routines
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lower guidance scores on the Diabetes Family Behavior Scale
Number of subjects: 40

Group type: COMPARATOR
Intervention: Higher impact and worry scores on the Diabetes Quality of Life for Youth Scale
Number of subjects: 40
Study: 8746180

Group type: EXPERIMENTAL
Intervention: Topical fluoridation with 2% NaF solution before orthodontic band cementation with zinc phosphate cement
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Orthodontic band cementation with glass ionomer cement
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no dental procedures)
Number of subjects: 21
Study: 2736431

Group type: EXPERIMENTAL
Intervention: Azelastine 8.8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 798330

Group type: EXPERIMENTAL
Intervention: High dose intravenous methylprednisolone therapy at the time of kidney transplantation
Number of subjects: 45
Study: 31567176

Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (e.g., spironolactone)
Number of subjects: 168
Study: 30841856

Group type: EXPERIMENTAL
Intervention: Flexible non-linear models within the Prentice framework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penalized likelihood approaches
Number of subjects: 0
Study: 28522338

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 3693

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 3693
Study: 25386713

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g·kg·d) during resistance training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo during resistance training
Number of subjects: 47
Study: 24353047

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100‐250 mg bid)
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Oxycodone HCl CR (20‐50 mg)
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2968
Study: 21530799

Group type: EXPERIMENTAL
Intervention: NO dietary supplement Neo40 Daily®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18427723

Group type: EXPERIMENTAL
Intervention: Tacrolimus (oral, ≤3 mg once daily for 76 weeks)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mizoribine (previous treatment)
Number of subjects: 115
Study: 22089267

Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (20-10-10 mg/kg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard-dose ibuprofen (10-5-5 mg/kg/day)
Number of subjects: 70
Study: 15764851

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study: 12446161

Group type: EXPERIMENTAL
Intervention: Eccentric phase of arm elevation at 100 degrees
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Eccentric phase of arm elevation at 120 degrees
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Eccentric phase at 80 degrees
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Eccentric phase at 100 degrees
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Eccentric phase at 120 degrees
Number of subjects: 52

Group type: COMPARATOR
Intervention: Symptomatic group compared to healthy group
Number of subjects: 52
Study: 9648050

Group type: EXPERIMENTAL
Intervention: NNC 01-0687 (dopamine D1 antagonist)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8054328

Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isomalt
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 10
Study: 2645016

Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 61
Study: 824215

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (DZ)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 33
Study: 29227351

Group type: EXPERIMENTAL
Intervention: PECS block with 30 ml of levobupivacaine 0.25% after induction of anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PECS block with propofol-remifentanil anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PECS block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline mock block (Control group)
Number of subjects: 60
Study: 27727281

Group type: EXPERIMENTAL
Intervention: Nurse-led telecoaching program
Number of subjects: 574
Study: 25245591

Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS) over auditory cortex, 20 min, 2 mA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (sham stimulation)
Number of subjects: 14
Study: 22639988

Group type: EXPERIMENTAL
Intervention: Welfare rights advice service
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study: 20545689

Group type: EXPERIMENTAL
Intervention: Dietary supplement (DS) containing Lactobacillus johnsonii (La1) and carotenoids for 10 weeks
Number of subjects: 139
Study: 17881390

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study: 15778071

Group type: EXPERIMENTAL
Intervention: Nurse-led (protocol-directed) weaning
Number of subjects: 7

Group type: COMPARATOR
Intervention: Medical-led weaning
Number of subjects: 7
Study: 12089891

Group type: COMPARATOR
Intervention: Captopril (C)
Number of subjects: 93
Study: 9974369

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - nadroparin, 85 anti-Xa IU/kg s.c. once daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Oral anticoagulant (OA) - acenocoumarol
Number of subjects: 202
Study: 7673609

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 4 weeks, followed by famotidine 20 mg twice daily for 4 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Famotidine 20 mg twice daily for 4 weeks, followed by lansoprazole 30 mg once daily for 4 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lansoprazole after switching from famotidine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 54

Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 54
Study: 2206878

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVGG) 800 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous albumin
Number of subjects: 10
Study: 7193003

Group type: EXPERIMENTAL
Intervention: Test preparation A (Acetylsalicylic acid + glycine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Test preparation B (Microencapsulated Acetylsalicylic acid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both ASA preparations (1000 mg ASA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test preparation A
Number of subjects: 20

Group type: COMPARATOR
Intervention: Test preparation B
Number of subjects: 20
Study: 31809479

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 4728

Group type: COMPARATOR
Intervention: Bivalirudin plus GPI
Number of subjects: 4728

Group type: COMPARATOR
Intervention: Heparin plus GPI
Number of subjects: 4728

Group type: EXPERIMENTAL
Intervention: Biomarker-positive patients
Number of subjects: 4728
Study: 31132105

Group type: EXPERIMENTAL
Intervention: Standardized meal (5025 kJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 18
Study: 28789492

Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg/d)
Number of subjects: 1421

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1421
Study: 25808394

Group type: COMPARATOR
Intervention: Pregabalin CR 330 mg alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pregabalin CR 330 mg co-administered with erythromycin 500 mg
Number of subjects: 18
Study: 23660206

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Higher white blood cell count (WBC)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: History of alcohol drinking
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: High National Institute of Health stroke scale (NIHSS score)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: High total cholesterol (TC)
Number of subjects: 446
Study: 21421955

Group type: EXPERIMENTAL
Intervention: COACH intervention (Web-based risk assessments with personal coaching support)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: RealAge intervention (Web-based risk assessment and behavior-specific modules)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control group (printed health-promotion materials)
Number of subjects: 423
Study: 19535722

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary block
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study: 17891901

Group type: EXPERIMENTAL
Intervention: Hot environment (39 degrees C; RH 30%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cold environment (9 degrees C; RH 61%)
Number of subjects: 8
Study: 12639353

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg IV
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 1 mg/kg IM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg IM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eutectic mixture local anesthetic (EMLA) cream 15 g
Number of subjects: 100
Study: 10674777

Group type: COMPARATOR
Intervention: Atypical antipsychotics (risperidone, olanzapine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone, Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study: 8956371

Group type: EXPERIMENTAL
Intervention: Follicular phase (F)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Menstrual phase (M)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Luteal phase (L)
Number of subjects: 15
Study: 1610929

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 798

Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 798
Study: 3889748

Group type: EXPERIMENTAL
Intervention: Aztreonam (2 g intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Gentamicin (1.5 mg/kg intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg intravenously every six hours)
Number of subjects: 119
Study: 30799637

Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medicare or no insurance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Private insurance
Number of subjects: 0
Study: 29320646

Group type: COMPARATOR
Intervention: Frozen-embryo transfer
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Fresh-embryo transfer
Number of subjects: 2157
Study: 27769273

Group type: EXPERIMENTAL
Intervention: Communicating individual BRCA results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggregate BRCA result communication
Number of subjects: 0
Study: 25315204

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Gastric banding (GB)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Very low-calorie diet (VLCD)
Number of subjects: 62
Study: 23053638

Group type: EXPERIMENTAL
Intervention: EC‐D (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) × 4 cycles)
Number of subjects: 94

Group type: COMPARATOR
Intervention: EC‐DCb (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 75 mg/m(2) plus carboplatin AUC 6 × 4 cycles)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: EC‐D
Number of subjects: 94

Group type: COMPARATOR
Intervention: EC‐DCb
Number of subjects: 94
Study: 20803858

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18589560

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg
Number of subjects: 0
Study: 16078332

Group type: EXPERIMENTAL
Intervention: 99mTc-MDP uptake at baseline
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 99mTc-MDP uptake in upper and middle tertiles
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Kellgren-Lawrence grade 3 OA severity and greater than median WOMAC Pain score
Number of subjects: 174
Study: 11868924

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9820259

Group type: EXPERIMENTAL
Intervention: Moxibustion on acupoint BL 67 for 7 days (with additional 7 days if needed)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Moxibustion on acupoint BL 67
Number of subjects: 260

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 260
Study: 7715793

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 57
Study: 2652084

Group type: EXPERIMENTAL
Intervention: Spiramycin (100 mg/kg/day for 10 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 44
Study: 582709

Group type: EXPERIMENTAL
Intervention: Domperidone 50 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 31891963

Group type: EXPERIMENTAL
Intervention: OrthoPilot navigation system
Number of subjects: 60

Group type: COMPARATOR
Intervention: iASSIST navigation system
Number of subjects: 60
Study: 31122158

Group type: EXPERIMENTAL
Intervention: Healthy Recovery program
Number of subjects: 77

Group type: COMPARATOR
Intervention: Online depression program (control)
Number of subjects: 77
Study: 29218623

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: PET response after chemoradiation
Number of subjects: 63
Study: 26830197

Group type: EXPERIMENTAL
Intervention: Home-based lifestyle intervention program with motivational interviewing
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group (waitlisted)
Number of subjects: 401
Study: 23912506

Group type: EXPERIMENTAL
Intervention: Pre-operative urodynamic studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized office evaluation
Number of subjects: 0
Study: 22646975

Group type: EXPERIMENTAL
Intervention: Relaxation training intervention (3 sessions and an audio disc for home practice)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting-list control group (no treatment)
Number of subjects: 56
Study: 21140635

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional tonsillectomy
Number of subjects: 57
Study: 17982722

Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) 2 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Number of subjects: 202

Group type: COMPARATOR
Intervention: Cefotiam (CTM) 1 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Number of subjects: 202
Study: 15342674

Group type: EXPERIMENTAL
Intervention: CETP inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: CETP deficiency
Number of subjects: 0
Study: 11229617

Group type: EXPERIMENTAL
Intervention: delta9-THC (5.0 to 10.0 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9526990

Group type: EXPERIMENTAL
Intervention: Clip closure (Vascular Clip‐applier System)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard suture (running 6‐0 monofilament)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clip closure
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard suture
Number of subjects: 16